Hemp 15 mg & 50 mg Capsule Absorption

Not Applicable

Completed

• Conditions: Absorption; Chemicals
• Interventions: Dietary Supplement: 15 mg/g Full Spectrum Hemp Extract; Dietary Supplement: 50 mg/g Full Spectrum Hemp Extract

• Registration Number: NCT05076890
• Lead Sponsor: Gaia Herbs Inc.

Brief Summary

This study is intended to investigate the absorption of cannabidiol (CBD) and cannabidiol acid (CBD-A) in plasma from an oral delivery of a single dose of full spectrum hemp extract at two concentrations over a 4-hour timeline.

Detailed Description

This study is designed to determine the time to maximum plasma concentration of CBD and CBD-A after an oral dose of standardized full spectrum hemp extract over a 4-hour timeline. This study is designed to include two arms. Each arm will be delivered a different concentration of standardized full spectrum hemp extract, either 15 mg or 50 mg. Throughout the course of the study all participants will be asked to provide four (4) plasma samples, 10 randomly selected participants will be asked to provide five (5) plasma samples. Samples will then be evaluated using a validated LC-MS/MS method to develop a blood concentration time curve in order to determine time to reach maximum blood concentration. This trial is double-blinded with two arms enrolling only healthy individuals. The participants randomized for a fifth blood draw will be randomly selected from these two arms.

Study Timeline

• Study Start: 2021-08-26
• Study First Submitted: 2021-09-30
• Study First Submitted QC: 2021-10-12
• Study First Posted: 2021-10-13
• Primary Completion: 2022-03-26
• Study Completion: 2022-03-26
• Status Verified: 2022-08
• Last Update Submitted: 2023-02-27
• Last Update Posted: 2023-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Provision of signed and dated informed consent form.
2. Stated willingness to comply with all study procedures and availability for the duration of the study.
3. Ages 18 - 65.
4. In good general health as evidenced by medical history as indicated by oral confirmation of study participant.
5. Ability and willingness to suspend the use of any other herbal dietary supplements for 48 hours prior the first clinical visit associated with this study.
6. Ability and willingness to abstain from alcohol use for 12 hours prior to the first clinical visit.
7. Cannabis and CBD naïve for 60 days or more prior to enrolling in the study.
8. Ability and willingness to abstain from food for 6 hours prior to the first clinical visit.

Exclusion Criteria

1. Current use of regular medication for a chronic condition.
2. Current pregnancy or lactation.
3. Plans to become pregnant during the intended duration of the study.
4. Known allergic reactions to hemp flower.
5. Known severe food allergies.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
15 mg/g Full Spectrum Hemp Extract	15 mg/g Full Spectrum Hemp Extract	A single capsule of 15 mg/g Full Spectrum Hemp Extract will be delivered.
50 mg/g Full Spectrum Hemp Extract	50 mg/g Full Spectrum Hemp Extract	A single capsule of 50 mg/g Full Spectrum Hemp Extract will be delivered.

Primary Outcome Measures

Name	Time	Method
Time to maximum plasma concentration	Over 4 hours	To determine the time to maximum plasma concentration of cannabidiol (CBD) and cannabidiol acid (CBD-A) from an oral delivery of a single dose of standardized 15 mg or 50 mg full spectrum hemp extract

Secondary Outcome Measures

Name	Time	Method
Detectable THC	Over 4 hours	To determine if the oral delivery of a full spectrum hemp extract standardized to less than 0.3% ∆\^9- tetrahydrocannabinol (THC) results in detectable amounts of THC in plasma.

Trial Locations

Locations (1)

Appalachian College of Pharmacy; 🇺🇸 Oakwood, Virginia, United States